Cargando…
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients. Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population me...
Autores principales: | Reboursiere, Emilie, Bras, Fabien Le, Herbaux, Charles, Gyan, Emmanuel, Clavert, Aline, Morschhauser, Franck, Malak, Sandra, Sibon, David, Broussais, Florence, Braun, Thorsten, Fornecker, Luc-Matthieu, Garidi, Reda, Tricot, Sabine, Houot, Roch, Joly, Bertrand, Abarah, Wajed, Choufi, Bachra, Pham, Anne-Dominique, Gac, Anne-Claire, Fruchart, Christophe, Marin, Emilie, Safar, Violaine, Parcelier, Anne, Maisonneuve, Hervé, Bachy, Emmanuel, Cartron, Guillaume, Jaccard, Arnaud, Tournilhac, Olivier, Rossi, Cédric, Schirmer, Luciane, Martignoles, Jean-Alain, Gaulard, Philippe, Tilly, Hervé, Damaj, Gandhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356759/ https://www.ncbi.nlm.nih.gov/pubmed/27458168 http://dx.doi.org/10.18632/oncotarget.10764 |
Ejemplares similares
-
Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment
por: Choufi, Bachra, et al.
Publicado: (2019) -
P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
por: Cartron, G., et al.
Publicado: (2022) -
Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma
por: Alsuliman, Tamim, et al.
Publicado: (2018) -
S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023) -
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
por: Johnson-Ansah, Hyacinthe, et al.
Publicado: (2022)